Product Reports Resources Pricing Login Book a demo

Genmab

Biotech & Life Sciences · Copenhagen, Denmark · Founded 1999 · IPO 2000

Differentiated human antibody therapeutics for the treatment of cancer

Valuation $21B
Revenue $4.14B
EBITDA $1.27B
Power Law Decacorn$10B+ valuation tier Thoroughbred$100M+ revenue
Knowledge graph
Analysis Europe's Decacorns & Centicorns — the Map Aug 23, 2026

Talent graph

Genmab's talent

Book a demo to see the people
Employees mapped 2,989 incl. 52 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 18 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Genmab's cap table

Sourced from Dealroom's funding history.

Series A 6 investors entered at this stage
Lombard Odier
Dansk Erhvervsinvestering
Medicxi
Apax Partners
LODH Immunology Fund
BankInvest

Ownership

Who owns Genmab

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).

7.5% BLACKROCK, INC.

“Other / undisclosed” is the 92.5% not attributed to a named shareholder. See the full cap table on Dealroom →

Global footprint

Where Genmab has talent and traffic

Workforce by country
25 countries with
team presence
🇺🇸 United States39.9%
🇳🇱 Netherlands29.8%
🇩🇰 Denmark22.3%
🇯🇵 Japan3.1%
🇸🇪 Sweden1.1%
Top 5 of 25 shown
Web traffic by country
100K monthly visits
across markets
🇺🇸 United States28.1%
🇩🇰 Denmark26.9%
🇳🇱 Netherlands11.8%
🇯🇵 Japan6.5%
🇦🇺 Australia4.4%
Top 5 markets shown

Patent intelligence

$488M patent portfolio · 295 active families

Estimated portfolio value
$488M
2.3% of market cap · 72.1× larger than top peer AbSci ($7M)
295 active patent families
Where Genmab innovates Antiendomysial antibodiesBispecific antibodyCD3Cancer researchCarcinosis

Where Genmab concentrates vs peers

Each axis is a top-10 topic across Genmab and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Genmab's 2 investments and acquisitions.

Every disclosed deal where Genmab appeared as a backer or acquirer, 2024–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Genmab's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Genmab's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Genmab

        An AI-synthesized read of the highest-engagement posts about Genmab on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Genmab on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles